Please login to the form below

Not currently logged in

Lilly testosterone gel approved

Eli Lilly and Acrux have received US approval for Axiron, the first approved testosterone replacement therapy topically applied to the underarm

Lilly and the Australian drug-delivery company Acrux have received US Food and Drug Administration (FDA) approval for Axiron (testosterone), the first approved testosterone replacement therapy that is topically applied to the underarm.

The drug has been approved for use by men over the age of 18 who suffer from certain conditions associated with a deficiency or absence of testosterone,  including primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).

The product is an alcohol-based solution applied once daily using a metered dose applicator.

The marketing application for Axiron included phase III data from a 120-day clinical study showing that 84 per cent of men who completed the study achieved average serum testosterone concentration within the normal range. The most common adverse reactions were skin application site reactions, increased red blood cell count, headache, diarrhoea, vomiting and an increase in blood level of prostate specific antigen.

The labelling for Axiron will carry a boxed warning about the risks of secondary exposure to the drug. The warning states that Axiron can transfer from the patient's body to others who come into contact with the area where it was applied, and that contact with topical testosterone products has produced early signs of puberty in young children.

Under a deal that was signed while the Axiron marketing application was being reviewed by the FDA, Lilly obtained exclusive worldwide rights to commercialize the drug. The deal called for a $50m upfront payment, a $3m payment on the transfer of manufacturing assets, a milestone payment of up to $87m tied to FDA approval, up to $195m in potential commercialization milestones, and royalties on sales.

24th November 2010


PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...